News | February 10, 2014

ViewRay MRI-Guided Radiation Therapy Used to Treat Cancer Patients

ViewRay MRI-Guided Radiation Therapy System Siteman Cancer Center
February 10, 2014 — The ViewRay system, a MRI-guided radiation therapy system, is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo. The ViewRay system provides a combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. 
MRI-guided radiation therapy enables clinicians to see a patient’s internal anatomy in real-time and keep radiation beams on target when the tumor moves during treatment. One of the initial treatments being delivered on the ViewRay system is stereotactic body radiation therapy (SBRT) for lung cancer. SBRT uses a few very high doses of radiation are delivered to small, well-defined tumors to kill cancer cells while minimizing exposure to surrounding healthy organs.
“Real-time MR guidance offers a way to treat tumors that move with respiration,” said Jeffrey Bradley, M.D., S. Lee Kling Professor of Radiation Oncology at Siteman Cancer Center and Washington University School of Medicine. “Our physicians and physicists report the ability to see tumors move in real-time during the entire treatment. This helps to ensure that tumor targets are hit and healthy tissue is spared.”
The ViewRay system provides continuous soft-tissue imaging during radiation therapy using MRI-guidance, so that clinicians are able to see exactly where the radiation dose is being delivered and adapt to changes in the patient’s anatomy. 
For more information:,

Related Content

ASTRO Issues Clinical Guideline for Whole Breast Radiation Therapy
News | Radiation Therapy | March 12, 2018
The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast...
Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Imaging Plays Key Role in Evaluating Injuries at Olympics
News | Orthopedic Imaging | February 28, 2018
The Olympic Games give elite athletes a chance at athletic triumph, but also carry a risk of injury. When injuries...
MD Anderson and RaySearch Partner to Advance Adaptive Radiation Therapy
News | Treatment Planning | February 26, 2018
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories announced a new strategic alliance with...
Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
The U.S. Food and Drug Administration (FDA) has cleared GOKnee3D, a magnetic resonance imaging (MRI) application from...
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Overlay Init